Abstract: The present invention provides liposomes that are useful for delivery of bioactive agents such as therapeutics. Among others, the liposomes of the invention are capable of delivering their payload at sites of increased secretory phospholipase A2 (sPLA2) activity, because phospholipase A2 (PLA2) will hydrolyse lipids of the liposome. Thus, the liposomes of the invention may e.g. be used in relation to cancer therapy. Another aspect of the invention is a liposomal formulation comprising the liposome of the invention. Still another aspect is a method of producing a liposomal formulation of the invention.
Type:
Grant
Filed:
February 10, 2020
Date of Patent:
November 16, 2021
Assignee:
LiPlasome Pharma ApS
Inventors:
Anders Falk Vikbjerg, Sune Allan Petersen, Fredrik Melander, Jonas Rosager Henriksen, Kent Jørgensen
Abstract: The present invention provides liposomes that are useful for delivery of bioactive agents such as therapeutics. Among others, the liposomes of the invention are capable of delivering their payload at sites of increased secretory phospholipase A2 (sPLA2) activity, because phospholipase A2 (PLA2) will hydrolyse lipids of the liposome. Thus, the liposomes of the invention may e.g. be used in relation to cancer therapy. Another aspect of the invention is a liposomal formulation comprising the liposome of the invention. Still another aspect is a method of producing a liposomal formulation of the invention.
Type:
Application
Filed:
May 25, 2009
Publication date:
January 12, 2012
Applicant:
LIPLASOME PHARMA APS
Inventors:
Anders Falk Vikbjerg, Sune Allan Petersen, Fredrik Melander, Jonas Rosager Henriksen, Kent Jørgensen